Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Graft Polymer (UK) PLC ( (GB:SVNS) ) just unveiled an announcement.
Solvonis Therapeutics plc has announced the exercise of warrants over 20,000,000 new ordinary shares, raising £20,000 in new funds. The company is preparing for these shares to be admitted to trading on the London Stock Exchange. This development is part of Solvonis’s broader strategy to enhance its financial position and support its ongoing clinical programs, which include a Phase 3 trial for severe Alcohol Use Disorder and a preclinical program for PTSD. The move is expected to strengthen Solvonis’s industry positioning and provide additional resources for its innovative R&D pipeline.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, the company is advancing a pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions. Its lead programs address Alcohol Use Disorder and Post-Traumatic Stress Disorder, with significant unmet needs across the UK, US, and EU4.
Average Trading Volume: 83,812,368
Technical Sentiment Signal: Buy
Current Market Cap: £19.5M
Find detailed analytics on SVNS stock on TipRanks’ Stock Analysis page.